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Background. Patients with suspected tuberculosis are often overtreated with antituberculosis drugs. We evaluated the diagnostic 
value of the focused assessment with sonography for HIV-associated tuberculosis (FASH) in rural Tanzania.
Methods. In a prospective cohort study, the frequency of FASH signs was compared between patients with confirmed tuber-
culosis and those without tuberculosis. Clinical and laboratory examination, chest x-ray, Xpert MTB/RIF assay, and culture from 
sputum, sterile body fluids, lymph node aspirates, and Xpert MTB/RIF urine assay was done.
Results. Of 191 analyzed patients with a 6-month follow-up, 52.4% tested positive for human immunodeficiency virus, 21.5% 
had clinically suspected pulmonary tuberculosis, 3.7% had extrapulmonary tuberculosis, and 74.9% had extrapulmonary and pul-
monary tuberculosis. Tuberculosis was microbiologically confirmed in 57.6%, probable in 13.1%, and excluded in 29.3%. Ten of 
eleven patients with splenic or hepatic hypoechogenic lesions had confirmed tuberculosis. In a univariate model, abdominal lym-
phadenopathy was significantly associated with confirmed tuberculosis. Pleural- and pericardial effusion, ascites, and thickened 
ileum wall lacked significant association. In a multiple regression model, abnormal chest x-ray (odds ratio [OR] = 6.19; 95% confi-
dence interval [CI], 1.96–19.6; P < .002), ≥1 FASH-sign (OR = 3.33; 95% CI, 1.21–9.12; P = .019), and body temperature (OR = 2.48; 
95% CI, 1.52–5.03; P = .001 per °C increase) remained associated with tuberculosis. A combination of ≥1 FASH sign, abnormal chest 
x-ray, and temperature ≥37.5°C had 99.1% sensitivity (95% CI, 94.9–99.9), 35.2% specificity (95% CI, 22.7–49.4), and a positive and 
negative predictive value of 75.2% (95% CI, 71.3–78.7) and 95.0% (95% CI, 72.3–99.3).
Conclusions. The absence of FASH signs combined with a normal chest x-ray and body temperature <37.5°C might exclude 
tuberculosis.
Keywords. FASH; sonography; sub-Saharan Africa; tuberculosis.
Tuberculosis remains one of the world’s deadliest communi-
cable diseases. In 2017, an estimated 10 million people fell ill 
with tuberculosis worldwide, and 1.6 million died of the disease 
[1]. In resource-limited settings with high tuberculosis preva-
lence, up to half of patients with suspected disease are treated 
with antituberculosis drugs without microbiological confirma-
tion, and 30%–60% of these empirically treated patients do not 
have active tuberculosis [2, 3]. Among reasons for the decision 
to treat without a positive test result are limited availability 
and reduced sensitivity of microbiological tests, particularly 
in patients coinfected with human immunodeficiency virus 
(HIV) or with suspected extrapulmonary tuberculosis [4–8]. 
The overtreatment of patients without tuberculosis is typically 
followed by a delay or lack of diagnosis of the real under-
lying disease, causing unnecessary drug exposure, side effects, 
and costs.
Focused Assessment with Sonography for HIV-associated 
Tuberculosis (FASH) was developed as a method to detect signs 
of extrapulmonary tuberculosis, which can be learned and 
performed by personnel with little or no previous experience in 
ultrasonography [9]. The FASH consists of a rapid sonographic 
evaluation of the abdomen, pleural space, and heart, to iden-
tify pleural and pericardial effusion, abdominal lymphadenop-
athy, hypoechogenic lesions in the spleen and the liver, ascites, 
and thickening of the bowel wall [10]. Some of these signs have 
been reported to occur in the majority of HIV-positive patients 
with suspected extrapulmonary tuberculosis, but tuberculosis 
was microbiologically confirmed in only a minority of those 
patients [11–14].
The diagnostic value of FASH in patients with tuberculosis 
has not been evaluated to date [15]. To address this need, we 
performed a prospective observational cohort study of patients 
with suspected tuberculosis and 6-month follow-up in a rural 
region in Tanzania. In particular, we aimed (1) to compare the 
frequency of sonographic signs of extrapulmonary tuberculosis 
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in patients with confirmed tuberculosis to patients with no tu-
berculosis and (2) to determine the sensitivity, specificity, and 
predictive values of FASH.
METHODS
Study Site
This prospective observational study was performed at the 
St. Francis Referral Hospital in Ifakara, Tanzania. The hospital 
serves a rural population of approximately 1 million people living 
in the Kilombero, Ulang, and Malinyi districts as a referral center. 
The hospital has 360 beds, runs an emergency department, and 
includes the Chronic Diseases Clinic Ifakara, which specializes in 
HIV and tuberculosis management [16, 17].
Study Population
Human immunodeficiency virus-positive and -negative adults 
aged ≥18 years presenting to any department of the St. Francis 
Referral Hospital or to the Chronic Diseases Clinic of Ifakara 
and fulfilling the following criteria were eligible: (1) suspected 
pulmonary tuberculosis, defined as presence of fever of any 
duration and/or night sweats during 3 weeks within the last 4 
weeks, and/or weight loss, together with cough of any duration 
and/or hemoptysis or infiltrate on chest x-ray; (2) suspected 
extrapulmonary tuberculosis, defined as presence of ≥1 of 
the following signs or symptoms: fever of any duration, night 
sweats during 3 weeks within the last 4 weeks, weight loss, 
lymphadenopathy, abdominal pain, or ascites, or neurolog-
ical symptoms, presence of severe anemia (hemoglobin <8  g/
dL) in an HIV-infected patient under antiretroviral treatment 
[18], with no cough, infiltrate in chest x-ray, or other obvious 
clinical explanation for those signs and symptoms listed above; 
(3) suspected combination of pulmonary and extrapulmonary 
tuberculosis, defined as presence of fever of any duration and/
or night sweats during 3 weeks within the last 4 weeks, and/
or weight loss, together with pulmonary and extrapulmonary 
signs and symptoms. Pregnant women, patients who refused 
to participate, and patients under pre-existing treatment with 
antituberculosis drugs were excluded.
Study Procedures
Patients were consecutively recruited from routine care during 
1  year starting from July 2016. All included patients were 
interviewed and examined according to a standardized, prede-
fined questionnaire. Axillary body temperature was measured 
with a digital thermometer. Chest x-ray with posterior-anterior 
projection was performed on the day of enrollment together 
with an HIV test (SD Bioline HIV 1/2 3.0; Abbott), which was 
confirmed by a Uni-Gold HIV Rapid Test (Trinity Biotech), if 
positive. Blood tests for hemoglobin, creatinine, and alanine 
aminotransferase were performed using Reflotron (Roche, 
Basel, Switzerland). All chest x-rays were reviewed and analyzed 
by R.N., M.W., and M.R., the last 2 of whom are board-certified 
physicians. Unclear findings were discussed and interpreted by 
this team.
At enrollment, early morning urine and sputum samples 
were collected from all patients. If spontaneous sputum was not 
available, sputum was induced by inhalation of nebulized 3% 
saline solution. To ensure consistent sputum quality, a video 
(https://www.youtube.com/watch?v=2 sd2d2_pNBA) on how 
to deliver sputum was shown to all patients. In case of pleural 
or pericardial effusion, ascites, lymphadenopathy, or menin-
gitis, ultrasound-guided puncture and fluid aspiration was 
performed.
All sputum and aspirated fluid samples were analyzed by 
Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA). In addi-
tion, sputum was processed by adding cetylpiridium chloride 
and N-acetyl-l-cysteine-sodium hydroxide and inoculated on 
Löwenstein-Jensen medium [19]. Sterile fluids (pleural, per-
icardial, and cerebrospinal fluids, ascites, and lymph node 
aspirates) were inoculated into liquid culture using bacteria 
growth indicator tube (MGIT) with a BACTEC 960 Instrument 
(BD Microbiology Systems, Sparks, MD). Urine was examined 
with Xpert MTB/RIF assay after centrifugation. Adenosine de-
aminase (Diazyme, Poway, CA) was measured in pleural, as-
citic, and pericardial fluids.
All patients received a sonographic examination according 
to the FASH protocol (see Supplementary Table S1), which was 
performed by R.N.  and F.D. The examination was supervised 
by M.R., either in person or by reviewing recorded images and 
video clips. R.N. and M.R. are board-certified sonographers. All 
examinations were performed with a Mindray M7 ultrasound 
machine (Mindray, Shenzhen, China). A  convex array probe 
C5-2s was used, except for sonography of the ileum, where a 
linear array 7L-4s probe was used. All sonographic examinations 
were done prior to sample taking, and microbiological results 
were not available to the sonographers. Clinical information 
could not be masked to the sonographers, but it was masked to 
the laboratory personnel performing microbiological tests.
All data were entered into standardized electronic 
questionnaires (EpiData). During follow-up, decisions on 
whether to administer antituberculosis treatment were 
considered by the patients’ treating physicians, who were not 
blinded to the results of the sonographic examination. Patients 
were scheduled for follow-up visits 2 and 6 months after enroll-
ment. If patients missed their appointment, they were traced 
by repeated phone calls or physically by visiting their homes 
by motorcycle. During follow-up visits, clinical evaluation and 
FASH were done at 2 and 6 months.
Definitions
FASH Signs
 Original FASH signs consisted of pleural or pericardial effu-
sion, ascites, abdominal lymph nodes >1.5 cm, hyperechogenic 
lesions in the liver or spleen, ileum wall thickening >4 mm, or 
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destructed ileum wall architecture. In addition, we systemati-
cally evaluated the presence of splenomegaly, hepatomegaly, 
and pleural or pericardial fibrin strands in presence of effusion.
Confirmed tuberculosis was defined as ≥1 positive microbio-
logical result from any site confirmed by Xpert MTB/RIF assay 
and/or bacteriologic culture (growth of Mycobacterium tuber-
culosis) in sputum, pleural fluid, ascites, cerebrospinal fluid, 
urine, or lymph node aspirate. In addition, the identification of 
acid-fast bacilli in sputum by another health center or adeno-
sine deaminase (ADA) ≥40 U/mL in pleural fluid [20], ≥35 U/
mL in pericardial fluid [4], and ≥30 U/mL in ascitic fluid [21] 
were accepted as microbiological confirmation.
Probable tuberculosis was defined as negative microbio-
logical tests in a patient in whom antituberculosis therapy 
(prescribed based on clinical suspicion or on chest x-ray) in the 
absence of an alternative diagnosis led to a resolution of clinical 
signs and symptoms, radiographic and sonographic signs, and 
to an increase in body weight documented 2 months after start 
of antituberculosis treatment.
No tuberculosis was defined as consistently negative micro-
biological tests in a patient in whom signs and symptoms, ra-
diographic, and sonographic signs subsided during follow-up 
and body weight increased without antituberculosis treatment, 
or if a patient with negative microbiological results had no res-
olution of clinical, radiographic, or sonographic signs during 
follow-up despite empirical antituberculosis treatment.
Abnormal chest x-ray was defined as the presence of upper 
lobe or any other infiltrate, cavernous lesion, miliary infiltrates, 
or pleural effusion on chest radiogram in posterior to anterior 
projection.
Statistical Analysis
Basic demographic characteristics, clinical and laboratory 
parameters, chest x-ray, and FASH signs were compared ac-
cording to diagnosis of (1) confirmed tuberculosis versus no 
tuberculosis and (2) confirmed or probable tuberculosis versus 
no tuberculosis. We chose confirmed tuberculosis as the pri-
mary outcome, because it reflects the microbiological reference 
standard. As a secondary outcome, we chose the composite ref-
erence standard of confirmed or probable tuberculosis as a clin-
ically relevant outcome [22]. We used χ2 test or Fisher’s exact 
test for categorical variables and the Mann-Whitney U test for 
continuous variables. Logistic regression was used to estimate 
the prediction of confirmed and confirmed or probable tuber-
culosis according to different clinical and radiological criteria 
including FASH. A  backward stepwise multivariable logistic 
regression analysis on the selected variables to form the pre-
diction model (entry criteria = P < .05; removal criteria = P ≥ 
.10) was used. We retained those variables that are known to be 
associated with tuberculosis (younger age, male sex, HIV infec-
tion, lower body mass index). Likelihood ratio tests were used 
to measure goodness of the fit of the regression models. Results 
are presented as crude and adjusted odds ratios (ORs) after 
adjusting for potential confounders as indicated. Finally, we 
checked the models for any interactions. Patients with missing 
baseline- or follow-up data were excluded from analysis. All 
analyses were performed using STATA software version 13 for 
Windows (Stata Corp., College Station, TX).
Ethical Statement
The study was approved by the Swiss ethics committee 
Ethikkommission Nordwest und Zentralschweiz (Nr 2015/243) 
and the ethics committees of the Ifakara Health Institute 
(Institutional Review Board, IHI/IRB/No 02-2016) and the 
National Institute for Medical Research, Tanzania (Ref. NIMR/
HQ/R.8a/Vol. IX/2244). All participants signed an informed 
consent form.
RESULTS
From July 2016 through to June 2017, 261 patients were 
enrolled. Seventy patients were excluded: 64 with negative 
microbiological results at baseline and insufficient follow-up 
information to classify them as confirmed, probable, or no tu-
berculosis, and 6 with insufficient baseline information. Overall, 
191 patients were included in the final analysis; of these, 100 
(52.4%) were HIV-positive and 36 (18.8%) were hospitalized. 
A  total of 41 (21.5%) patients were clinically suspected to 
have pulmonary tuberculosis only, 7 (3.7%) were suspected to 
have extrapulmonary tuberculosis only, and 143 (74.9%) were 
suspected to have combined extrapulmonary and pulmonary 
tuberculosis. After 6  months follow-up, 110 (57.6%) patients 
had a final diagnosis of confirmed tuberculosis, 25 (13.1%) had 
a diagnosis of probable tuberculosis, and 56 (29.3%) had no tu-
berculosis (Figure 1).
Table 1 shows baseline characteristics according to the final 
diagnosis. Compared to patients with no tuberculosis, patients 
with confirmed tuberculosis were younger, were more likely to 
be male, had a lower body mass index, reported weight loss more 
frequently, were less likely to be HIV-positive, and had distinct 
clinical presentations (higher temperature, lower oxygen satu-
ration, more frequent lymphadenopathy, and abnormal chest 
x-ray). On sonography, patients with confirmed tuberculosis 
had significantly more signs of pleural effusion, pleural fibrin 
strands, abdominal lymphadenopathy, hepatomegaly, or ≥1 
original FASH sign than patients with no tuberculosis.
Of the 11 (6%) patients with hypoechogenic lesions in the 
liver or spleen (median diameter 10.3  mm, range 4–32  mm), 
all but 1 were HIV-positive, and all had confirmed (n = 10) or 
probable (n  =  1) tuberculosis. There was no difference in the 
occurrence of ascites between the 2 groups. Of the 110 patients 
with confirmed tuberculosis, only 7 (6.3%) had a body temper-
ature below 37.5°C together with a normal chest x-ray, and 6 
of these had a positive FASH. When patients with confirmed 
or probable tuberculosis were compared with patients without 
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tuberculosis, results were similar (see Supplementary Table S2). 
Supplementary Table S3 shows the baseline characteristics of 
the 64 patients lost to follow-up.
Association of Clinical, Radiographic, and Sonographic Signs With 
Confirmed Tuberculosis
Univariate and multivariate regression models of predictors 
of confirmed tuberculosis versus no tuberculosis are shown in 
Tables 2 and 3, respectively. In the univariate model, older age 
(OR = 0.67; 95% confidence interval [CI], 0.53–0.85; P < .001), fe-
male sex (OR = 0.46; 95% CI, 0.24–0.88; P = .020), body mass index 
(OR = 0.37; 95% CI, 0.23–0.59 ; P < .001, per 5 kg/m2 increase), 
HIV infection (OR = 0.46; 95% CI, 0.24–0.89; P = .023), and pres-
ence of abdominal symptoms (OR  =  0.27; 95% CI, 0.13–0.53; 
P < .001) were negatively associated with confirmed tuberculosis. 
Higher body temperature (OR = 3.2; 95% CI, 2.00–5.12; P < .001) 
and abnormal chest x-ray (OR = 6.32; 95% CI, 2.83–14.2; P < .001) 
were positively associated with confirmed tuberculosis. From the 
FASH signs, abdominal lymphadenopathy (OR = 7.14; 95% CI, 
1.62–31.5; P = .009) and ≥1 original FASH sign (OR = 3.11; 95% 
CI, 1.56–6.21; P = .001) was associated with confirmed tubercu-
losis. We found no significant association between pleural effu-
sion, pericardial effusion, ascites, or thickened ileum wall and 
confirmed tuberculosis. In the multivariate regression model, 
the association of increased body temperature (OR = 2.48; 95% 
CI, 1.52–5.03; P = .001 per each °C increase), pathological chest 
x-ray (OR = 6.19; 95% CI, 1.96–19.6; P = .002), and ≥1 original 
FASH signs (OR = 3.33; 95% CI, 1.21–9.12; P = .019) remained 
significant with confirmed tuberculosis. Supplementary Tables S4 
and S5 show the univariate and multivariate regression models of 
predictors of the composite outcome of confirmed or probable 
tuberculosis versus no tuberculosis. The results were similar ex-
cept that pleural effusion in FASH (OR = 3.63; 95% CI, 1.44–9.14; 
P = .006) and pleural fibrin strands (OR = 5.84; 95% CI, 1.33–25.6; 
P = .019) were significantly associated with confirmed or probable 
tuberculosis in the univariate model. Analyzing only patients with 
signs of extrapulmonary tuberculosis (N = 150), no relevant dif-
ference was found (data not shown).
Sensitivity, Specificity, and Predictive Values of Clinical, Radiographic, 
and Sonographic Signs
Table 4 shows sensitivity and specificity for the most important 
clinical and FASH signs. The combination ≥1 original FASH 
sign, abnormal chest x-ray, and body temperature ≥37.5°C had 
a sensitivity of 99.1% (95% CI, 94.9–99.9), a specificity of 35.2% 
(95% CI, 22.7–49.4), a positive predictive value of 75.2% (95% 
CI, 71.3–78.7), and a negative predictive value of 95.0% (95% 
CI, 72.3–99.3). This did not change substantially if the com-
posite outcome confirmed or probable tuberculosis versus no 
tuberculosis was analyzed (see Supplementary Table S6).
Microbiological Results in Patients With Confirmed Tuberculosis
Of 110 patients with a microbiologically confirmed tubercu-
losis, 80 were sputum-positive. Thirty patients had no sputum 
or a negative sputum assay. Of these 30 patients, 5 had a positive 
Xpert MTB/RIF assay in urine, 3 had a positive assay in pleural 
Enrolled patients
N = 261
Included patients
N = 255
Insucient baseline information (N = 6)
No confirmed diagnosis (N = 64)
32 HIV positive (7 PTB, 1 EPTB, 24 EPTB and PTB)
32 HIV negative (7 PTB, 2 EPTB, 23 EPTB and PTB)
HIV positive
N = 100 (52.4%)
HIV negative
N = 91 (47.6%)
PTB
N = 15/100 (15.0%)
EPTB and PTB*
N = 85/100 (85.0%)
PTB
N = 26/91 (28.6%)
EPTB and PTB**
N = 65/91 (61.4%)
Confirmed TB
Probable TB
No TB
5/15 (33.3%)
1/15 (6.7%)
9/15 (60.0%)
45/85 (52.9%)
13/85 (15.3%)
27/85 (31.8%)
19/26 (73.1%)
1/26 (3.8%)
6/26 (23.1%)
41/65 (63.1%)
*3 EPTB only, 82 EPTB and PTB
**4 EPTB only, 61 EPTB and PTB
10/65 (15.4%)
14/65 (21.5%)
Analysed patients
N = 191
Figure 1. Enrollment of patients. Patients are presented according human immunodeficiency virus (HIV) status and final diagnosis reached. No confirmed diagnosis, no 
confirmed tuberculosis (TB) at inclusion, and lost to follow-up; confirmed TB, microbiologically confirmed TB; PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis; 
EPTB and PTB, presence of EPTB and PTB in a patient.
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fluid, and 3 had a positive assay in lymph node aspirates. Positive 
sputum cultures were found in 9 patients with an initially nega-
tive Xpert MTB/RIF assay, confirmed to be M tuberculosis. In 7 
patients, tuberculosis was diagnosed by elevated ADA alone (3 
in pleural fluid, 2 in pericardial fluid, and 2 in ascitic fluid). One 
patient tested positive only on pleural fluid culture, and 1 patient 
Table 1. Patient’s Characteristics According to Diagnosis Confirmed TB Versus No TB
Confirmed TB No TB
 N = 110 N = 56  
 Characteristic N % or IQR N % or IQR  P Value
Median age, years 36.5 27.1–43.3 41.5 34.2–57.3 .002
Male sex 70 63.6 25 44.6 .019
Body mass index, kg/m2 18.3 16.7–20.6 21.2 19.1–23.8 <.001
HIV infection 50 45.5 36 64.3 .022
Symptoms Fever 74 67.3 36 64.3 .700
Cough 104 94.5 49 87.5 .110
Hemoptysis 20 18.8 10 17.9 .959
Dyspnea 55 50.0 30 53.6 .663
Chest pain 67 60.9 40 71.4 .181
Night sweats 74 67.3 29 51.8 .052
Weight loss 86 78.9 33 62.3 .024
Abdominal symptoms 44 40.0 40 71.4 <.001
Neurological symptoms 29 26.4 15 26.8 .954
Clinical signs Median temperature, °C 37.4 36.7–38.0 36.6 36.0–37.0 <.001
Median SaO2 97 95–98 98 96–98 .026
Pulmonary signsa 76 69.1 28 50.0 .016
Cardiac signsb 8 7.3 6 10.7 .451
Abdominal signsc 64 58.2 33 58.9 .926
Lymphadenopathyd 70 63.4 24 42.9 .011
Chest x-ray Upper lobe infiltrates 64 58.2 12 21.4 <.001
Cavernous lesion 36 32.7 1 1.8 <.001
Miliary infiltrates 3 2.2 1 1.8 .664
Other infiltrates 65 59.0 21 37.5 .077
Pleural effusion 23 20.9 6 10.7 .111
Clinical TB PTB 24 21.8 15 26.8 .061
EPTB 2 1.8 5 8.9
EPTB and PTB 84 76.4 36 64.3
Original FASH signs Pleural effusion 26 23.6 6 10.7 .046
Pericardial effusion 20 18.8 5 8.9 .086
Ascites 28 25.5 11 19.6 .404
Abdominal LN 23 20.9 2 3.6 .002
Hypoechogenic lesions in liver/spleen 10 9.1 0 - -
Ileum wall thickening 7 6.4 3 5.4 .604
Ileum wall destruction 6 5.4 4 7.1 .410
Additional sonographic signs Splenomegaly 29 26.3 16 29.1 .711
Hepatomegaly 58 52.7 20 35.7 .038
Pleural fibrin starnds 14 12.7 2 3.6 .047
Pericardial fibrin strands 2 1.8 0 - -
≥1 original FASH sign 61 55.5 16 28.6 .001
≥1 sonographic signe 88 80.0 38 67.9 .084
Number of sonographic signse 0 22 20.0 18 32.1 .038
1 34 30.9 21 37.5
2 16 14.6 7 12.5
≥3 38 34.5 10 17.9
P values in bold numbers indicate that the difference is statistically significant. 
Abbreviations: abdominal LN, abdominal lymph nodes >1.5 cm; EPTB, extrapulmonary tuberculosis; FASH, focused assessment with sonography for HIV-associated tuberculosis; HIV, human 
immunodeficiency virus; IQR, interquartile range; LN, lymph nodes; PTB, pulmonary tuberculosis, SaO2, oxygen saturation; TB, tuberculosis. 
aPulmonary signs included crackles, wheezing, pleural friction in lung auscultation, or dullness in lung percussion.
bCardiac signs were dilated jugular veins, lateralized apex beat, or heart murmur. 
cAbdominal signs included organomegaly, ascites, and abnormal bowel sound.
dLymphadenopathy was diagnosed if palpable enlarged axillary, cervical, or nuchal lymph nodes were present on physical examination.
ePresence of at least any of the original FASH sign and/or splenomegaly, hepatomegaly, or pleural- or pericardial fibrin strands.
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tested positive only on ascites culture. One patient had only a posi-
tive acid-fast bacilli microscopy (see Supplementary Table S7). We 
did not note any adverse events after puncturing procedures.
DISCUSSION
In this prospective, observational cohort study of HIV-
positive and -negative patients with suspected tuberculosis, 
we found that the combination of ≥1 original FASH sign, an 
abnormal chest-x ray, and a body temperature of ≥37.5°C had 
an excellent sensitivity and negative predictive value for tuber-
culosis. All but 1 patient with hypoechogenic splenic or he-
patic lesions had confirmed tuberculosis. The 2 most common 
FASH signs, abdominal lymphadenopathy and pleural ef-
fusion, were associated with tuberculosis, the latter with the 
Table 2. Predictors of Confirmed Tuberculosis Versus No Tuberculosis (Univariate Logistic Regression)
Predictor Odds Ratios 95% CI P Value
Age, per 10 years older 0.67 0.53–0.85 <.001
Female versus male 0.46 0.24–0.88 .020
Body mass index, per 5 kg/m2 increase 0.37 0.23–0.59 <.001
HIV infection 0.46 0.24–0.89 .023
Fever 1.14 0.58–2.24 .700
Cough 2.47 0.79–7.76 .120
Hemoptysis 1.02 0.44–2.36 .959
Dyspnea 0.87 0.45–1.65 .663
Chest pain 0.62 0.31–1.25 .182
Night sweats 1.91 0.99–3.69 .053
Weight loss 2.26 1.10–4.66 .026
Abdominal symptoms 0.27 0.13–0.53 <.001
Neurological symptoms 0.98 0.47–2.03 .954
Temperature, per each °C increase 3.20 2.00–5.12 <.001
SaO2 0.87 0.75–1.02 .071
Pulmonary signsa 2.23 1.15–4.33 .017
Cardiac signsb 0.65 0.22–1.98 .453
Abdominal signsc 0.97 0.50–1.86 .926
Lymphadenopathyd 2.33 1.20–4.49 .011
Chest x-ray Upper lobe infiltrates 5.09 2.41–10.8 <.001
Cavernous lesion 26.9 3.57–202.3 .001
Miliary infiltrates 1.54 0.15–15.3 .710
Other infiltrates 2.37 1.22–4.64 .011
Pleural effusion 2.16 0.82–5.68 .117
Abnormal chest x-ray 6.32 2.83–14.2 <.001
Original FASH signs Pleural effusion 3.58 0.99–6.70 .052
Pericardial effusion 2.27 0.80–6.40 .122
Ascites 1.39 0.63–3.07 .405
Abdominal LN 7.14 1.62–31.5 .009
 Mesenterial LN 1.77 1.27–2.45 .001
Additional sonographic signs Splenomegaly 0.87 0.41–1.79 .711
Hepatomegaly 2.01 1.03–3.89 .039
Pleural fibrin 3.94 0.86–17.9 .077
Ileum wall thickening 1.20 0.29–4.83 .797
Ileum wall destruction 0.50 0.20–2.77 .666
≥1 original FASH sign 3.11 1.56–6.21 .001
Number of any sonographic signe 0 - - -
1 1.32 0.58–3.02 .505
2 1.87 0.63–5.53 .258
≥3 3.11 1.22–7.91 .017
P values in bold numbers indicate that the association is statistically significant.
Abbreviations: CI, confidence interval; EPTB, extrapulmonary tuberculosis; FASH, focused assessment with sonography for HIV-associated tuberculosis; HIV, human immunodeficiency 
virus; LN, lymph nodes; PTB pulmonary tuberculosis; SaO2, oxygen saturation. 
aPulmonary signs included crackles, wheezing, pleural friction in lung auscultation, or dullness in lung percussion.
bCardiac signs included dilated jugular veins, lateralised apex beat, or heart murmur.
cAbdominal signs were organomegaly, ascites, and abnormal bowel sounds.
dLymphadenopathy included palpable enlarged axillary, cervical, or nuchal lymph nodes on physical examination.
ePresence of at least any of the original FASH criteria and/or splenomegaly, hepatomegaly, or pleural- or pericardial fibrin strands.
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composite outcome confirmed or probable tuberculosis only. 
This composite outcome is clinically relevant, because culture 
as the gold standard is not always available, and its sensitivity 
is suboptimal [22, 23].
The positive association between hypoechogenic splenic or 
hepatic lesions, abdominal lymphadenopathy, and pleural effu-
sion with tuberculosis is in agreement with a recently published 
study from India where 27% of 285 patients with confirmed or 
probable tuberculosis had pleural effusion, 14% had abdominal 
lymphadenopathy, and 6% had splenic or liver lesions [15]. The 
major difference to our study was the comparably low propor-
tion of HIV-infected patients (20%) and the lack of follow-up 
by ultrasound in that study. Previous studies in HIV-positive 
patients in South Africa and Italy have reported even higher 
rates of FASH signs with 76% abdominal lymphadenopathy 
and 41% spleen and 31% liver lesions [12, 13]. However, these 
populations were small, and microbiologically confirmed tu-
berculosis was present in only a minority of patients.
Although pericardial effusion was more than twice as fre-
quent in patients with tuberculosis as in patients without tuber-
culosis, we could not demonstrate a significant association in 
our study. Tuberculosis has been reported as the cause of per-
icardial effusions in 70% of South African patients, indicating 
other possible causes, eg, viral, malignancy, or connective tissue 
disease [24]. Thickened ileum wall might have been caused by 
other bacterial infections or chronic inflammatory diseases, and 
it was not associated with tuberculosis in our study. Ascites has 
a broad differential diagnosis, eg, pelvic inflammatory disease, 
liver or kidney disease, heart failure, or cancer [25, 26]. Thus, 
other diseases than tuberculosis should be considered and 
looked for in a patient with thickened ileum wall or ascites.
Fever and upper lobe infiltrate in chest x-ray are known signs 
of tuberculosis and were the strongest predictors of pulmonary 
tuberculosis in hospitalized HIV-positive and -negative patients 
in North America [27, 28]. Besides presence of cough and night 
sweats, fever of any duration was a predictor for tuberculosis in 
HIV-positive outpatients in Southeast Asia [29].
In contrast to the high sensitivity of the combination of 
FASH, chest x-ray, and body temperature, specificity of this 
combination and of most FASH signs was poor. Although 
the absence of sonographic and radiographic signs combined 
Table 3. Predictors of Confirmed Tuberculosis (n = 110 vs 56): Multivariate 
Logistic Regression
Predictor Odds Ratios 95% CI P Value
Age, per 10 years older 0.72 0.51–1.00 .054
Female versus male 0.75 0.38–2.67 .971
Body mass index, per 5 kg/m2 increase 0.87 0.74–1.03 .087
HIV infection 0.61 0.21–1.75 .361
Cough 2.63 0.50–13.7 .251
Night sweats 0.68 0.25–1.84 .444
Weight loss 0.77 0.22–2.74 .688
Temperature, per each °C increase 2.48 1.52–5.03 .001
Pulmonary signsa 1.10 0.39–3.05 .859
Abdominal signsb 0.71 0.26–1.90 .493
Lymphadenopathyc 1.68 0.58–4.83 .338
Abnormal chest x-rayd 6.19 1.96–19.6 .002
≥1 FASH sign 3.33 1.21–9.12 .019
Odds ratios were adjusted for all variables listed; ≥1 FASH sign, presence of at least 1 
original FASH sign. P values in bold numbers indicate that the association is statistically 
significant.
Abbreviations: CI, confidence interval; FASH, focused assessment with sonography for 
HIV-associated tuberculosis; HIV, human immunodeficiency virus.
aPulmonary signs included crackles, wheezing, pleural friction in lung auscultation, or dull-
ness in lung percussion.
bAbdominal signs included organomegaly, ascites, and abnormal bowel sound.
cLymphadenopathy was diagnosed if palpable enlarged axillary, cervical, or nuchal lymph 
nodes were present on physical examination.
dAbnormal chest radiogram included any infiltrate, cavernous lesions, miliary pattern, or 
pleural effusion.
Table 4. Sensitivity, Specificity, Predictive Values, and Accuracy of the Most Important Test Combinations Predicting Confirmed Tuberculosis (n = 166)
Predictor
Sensitivity Specificity PPV NPV Accuracy
% (95% CI) % (95% CI) % (95%CI) % (95%CI) % (95% CI)
≥1 FASH sign 55.5 (45.7–64.9) 60.6 (47.8–72.4) 70.1 (62.5–76.8) 44.9 (38.5–52.1) 57.4 (49.7–64.8)
Abnormal chest x-ray 88.8 (81.2–94.1) 44.4 (30.9–58.6) 76.0 (71.2–80.2) 66.7 (52.1–78.7) 73.9 (66.4–80.5)
Measured T ≥37.5° 41.8 (32.5–51.6) 96.4 (87.7–99.6) 95.8 (85.3–98.9) 45.8 (41.7–49.9) 60.2 (52.5–67.7)
Constitutional symptomsa 96.3 (90.9–98.9) 17.0 (8.1–29.8) 70.5 (67.8–73.1) 69.2 (42.1–87.5) 70.4 (62.7–77.3)
Cough 94.6 (88.5–97.9) 12.5 (5.2–24.1) 68.0 (65.6–70.3) 53.9 (29.2–76.8) 66.9 (59.2–74.0)
Lymphadenopathy in clinical exam 63.6 (53.9–72.6) 57.1 (43.2–70.3) 74.5 (67.6–80.3) 44.4 (36.4–52.8) 61.4 (53.6–68.9)
Constitutional symptomsa and T ≥37.5° 41.3 (31.9–51.1) 96.2 (87.0–99.5) 95.7 (85.0–98.9) 44.4 (40.3–48.5) 59.3 (51.3–66.9)
≥1 FASH sign and T ≥37.5° 75.5 (66.3–83.2) 67.9 (54.0–79.7) 82.2 (75.6–87.3) 58.5 (49.2–67.2) 72.9 (65.5–79.5)
Abnormal chest x-ray and T ≥37.5° 92.5 (85.8–86.7) 42.6 (29.3–56.8) 76.2 (71.6–80.2) 74.2 (57.9–85.7) 75.8 (68.4–82.2)
≥1 FASH sign and abnormal chest x-ray 98.1 (93.4–99.8) 37.0 (24.3–51.3) 75.5 (71.5–79.2) 90.9 (70.8–97.6) 77.6 (70.4–83.8)
≥1 FASH sign and abnormal chest x-ray and T ≥37.5° 99.1 (94.9–99.9) 35.2 (22.7–49.4) 75.2 (71.3–78.7) 95.0 (72.3–99.3) 77.6 (70.4–83.8)
Abbreviations: CI, confidence interval; FASH, focused assessment with sonography for HIV-associated tuberculosis; NPV, negative predictive value; PPV, positive predictive value; T, body 
temperature.
NOTE: ≥1 FASH sign, presence of at least 1 original FASH sign.
aHistory of weight loss, night sweat, or fever.
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with a temperature <37.5°C might lower the probability of 
tuberculosis substantially, the presence of those signs would 
not confirm it. On the other hand, Xpert MTB/RIF assay has 
a high specificity of up to 99% in sputum and body fluids, and 
it is easy to handle even under difficult working environments 
[30]. However, the sensitivity of the Xpert MTB/RIF assay 
is reduced in HIV-positive individuals, patients with 
paucibacillary disease, and in extrapulmonary tubercu-
losis with low amounts of mycobacteria in pleural and other 
body fluids [4–7]. In these circumstances, overtreatment 
would not be reduced by implementing the Xpert MTB/
RIF assay only, especially in an environment of high pretest 
probability for tuberculosis [2]. Thus, a diagnostic process 
including the combination of clinical, sonographic, radio-
graphic, and microbiological findings might increase the rate 
of appropriate decisions on whether to treat patients with 
antituberculosis drugs.
In case of negative microbiology, normal chest x-ray, and 
absent FASH signs or presence of ascites only, empirical 
antituberculosis therapy might be safely withheld, and fur-
ther tests such as full abdominal sonography and laboratory 
tests to examine for other diseases than tuberculosis might be 
done. In presence of pleural effusion, abdominal lymphad-
enopathy, or pericardial effusion, empirical antituberculosis 
therapy might be considered and started if tuberculoma 
in liver or spleen were detected. This is being studied 
in a randomized controlled trial (registration number: 
PACTR201712002829221).
Our study had limitations. First, 70 patients were excluded 
because of insufficient information or loss to follow-up. The 64 
patients lost to follow-up resembled the group of patients with 
tuberculosis. Therefore, independent predictors for tubercu-
losis remained stable in the statistical models. Second, be-
cause the study was observational, the performance of FASH 
might have affected physicians’ treatment choices, because the 
results were not blinded. Third, we could not verify tubercu-
losis as the cause for every single FASH sign in a patient with 
confirmed disease, because confirmed tuberculosis was de-
fined as ≥1 positive microbiological result, regardless where 
the sample was taken from. Furthermore, we cannot exclude 
(1) other disease agents in patients with probable tuberculosis 
or (2) drug resistance in patients who were classified as having 
no tuberculosis and did not improve on antituberculosis 
therapy. However, we did not find any drug resistance in our 
study population, and the estimated percentage of multidrug 
resistance cases in Tanzania is only 0.9% among new tubercu-
losis cases [1]. Fourth, we were not able to perform an analysis 
stratified by pulmonary and extrapulmonary tuberculosis, be-
cause three fourths of the patients had both pulmonary and 
extrapulmonary tuberculosis. Fifth, the study was done in a 
referral center, where the patient population might differ from 
primary care centers. Thus, results should be interpreted in 
this context. Finally, this was a single-center study done in 
rural Tanzania, and our results might not be generalizable to 
centers in higher-income countries.
CONCLUSIONS
In conclusion, the combination of ≥1 original FASH sign, an ab-
normal chest x-ray, and a body temperature of ≥37.5°C had an ex-
cellent sensitivity and negative predictive value for tuberculosis. Its 
absence may substantially decrease the probability of tuberculosis 
in HIV-positive and -negative patients with clinically suspected pul-
monary or extrapulmonary tuberculosis. This may help clinicians 
in deciding whether to withhold empirical antituberculosis therapy 
and might reduce overtreatment of tuberculosis.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
Acknowledgments
We thank Peele Stolt for language editing.
Author contributions. M. R. and M. W. contributed to study design, 
data collection, data analysis, and manuscript writing. R.  N.  contributed 
to manuscript writing, data collection, and data analysis. L. E. performed 
statistical analyses. F. D., F. B., G. S., H. M., W. G., and E. M. contributed 
to data collection. L.  K.  and D.  M.  performed microbiological tests. 
M. B. and K. R. contributed to study design and manuscript writing. D. H. 
P. contributed to manuscript writing.
Financial support. M.  R.  received the funding for the project and 
takes the responsibility overall. This work was funded by the Foundation 
Freiwillige Akademische Gesellschaft (Basel, Switzerland).
Potential conflicts of interest. All authors: No reported conflicts of in-
terest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. 
References
1. World Health Organization. Global tuberculosis report 2018. Available at: https://
www.who.int/tb/publications/global_report/en/. Accessed 12 April 2019.
2. Theron G, Peter J, Dowdy D, et al. Do high rates of empirical treatment under-
mine the potential effect of new diagnostic tests for tuberculosis in high-burden 
settings? Lancet Infect Dis 2014; 14:527–32.
3. Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes 
among TB suspects screened by a single point-of-care Xpert MTB/RIF at a pri-
mary care clinic in Johannesburg, South Africa. PLoS One 2013; 8:e65421.
4. Pandie S, Peter JG, Kerbelker ZS, et al. Diagnostic accuracy of quantitative PCR 
(Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase 
and unstimulated interferon-γ in a high burden setting: a prospective study. BMC 
Med 2014; 12:101.
5. Kohli M, Schiller I, Dendukuri N, et al. Xpert® MTB/RIF assay for extrapulmonary 
tuberculosis and rifampicin resistance. Cochrane Database Syst Rev 2018; 
8:CD012768.
6. Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary tu-
berculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 
CD009593.
7. Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detec-
tion of Mycobacterium tuberculosis and rifampicin resistance: a prospective 
multicentre diagnostic accuracy study. Lancet Infect Dis 2018; 18:76–84.
8. Walusimbi S, Bwanga F, De Costa A, et al. Meta-analysis to compare the accu-
racy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-
negative pulmonary tuberculosis. BMC Infect Dis 2013; 13:507.
9. Heller T, Wallrauch C, Lessells RJ, et al. Short course for focused assessment with 
sonography for human immunodeficiency virus/tuberculosis: preliminary results 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/6/4/ofz154/5427906 by W
W
Z Bibliothek (O
effentliche Bibliotherk der U
niversitÃ¤t Basel) user on 02 M
ay 2019
Sonography and Tuberculosis • ofid • 9
in a rural setting in South Africa with high prevalence of human immunodefi-
ciency virus and tuberculosis. Am J Trop Med Hyg 2010; 82:512–5.
10. Heller T, Wallrauch C, Goblirsch S, Brunetti E. Focused assessment with sonog-
raphy for HIV-associated tuberculosis (FASH): a short protocol and a pictorial 
review. Crit Ultrasound J 2012; 4:21.
11. Heller T, Goblirsch S, Wallrauch C, et al. Abdominal tuberculosis: sonographic 
diagnosis and treatment response in HIV-positive adults in rural South Africa. 
Int J Infect Dis 2010; 14 (Suppl 3):e108–12.
12. Heller T, Goblirsch S, Bahlas S, et al. Diagnostic value of FASH ultrasound and 
chest X-ray in HIV-co-infected patients with abdominal tuberculosis. Int J Tuberc 
Lung Dis 2013; 17:342–4.
13. Heller T, Wallrauch C, Brunetti E, Giordani MT. Changes of FASH ultrasound 
findings in TB-HIV patients during anti-tuberculosis treatment. Int J Tuberc 
Lung Dis 2014; 18:837–9.
14. Skoura  E, Zumla  A, Bomanji  J. Imaging in tuberculosis. Int J Infect Dis 2015; 
32:87–93.
15. Weber SF, Saravu K, Heller T, et al. Point-of-care ultrasound for extrapulmonary 
tuberculosis in India: a prospective cohort study in HIV-positive and HIV-
negative presumptive tuberculosis patients. Am J Trop Med Hyg 2018; 
98:266–73.
16. Letang  E, Kalinjuma  AV, Glass  TR, et  al. Cohort profile: the Kilombero and 
Ulanga antiretroviral cohort (KIULARCO)–a prospective HIV cohort in rural 
Tanzania. Swiss Med Wkly 2017; 147:w14485.
17. Vanobberghen  F, Letang  E, Gamell  A, et  al. A decade of HIV care in rural 
Tanzania: trends in clinical outcomes and impact of clinic optimisation in an 
open, prospective cohort. PLoS One 2017; 12:e0180983.
18. Kerkhoff  AD, Wood  R, Cobelens  FG, et  al. The predictive value of current 
haemoglobin levels for incident tuberculosis and/or mortality during long-term 
antiretroviral therapy in South Africa: a cohort study. BMC Med 2015; 13:70.
19. Hiza  H, Doulla  B, Sasamalo  M, et  al. Preservation of sputum samples with 
cetylpyridinium chloride (CPC) for tuberculosis cultures and Xpert MTB/RIF in 
a low-income country. BMC Infect Dis 2017; 17:542.
20. Gui  X, Xiao  H. Diagnosis of tuberculosis pleurisy with adenosine deami-
nase (ADA): a systematic review and meta-analysis. Int J Clin Exp Med 2014; 
7:3126–35.
21. Tao L, Ning HJ, Nie HM, et al. Diagnostic value of adenosine deaminase in ascites 
for tuberculosis ascites: a meta-analysis. Diagn Microbiol Infect Dis 2014; 79:102–7.
22. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus 
pranii in tuberculous pericarditis. N Engl J Med 2014; 371:1121–30.
23. Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a ra-
diometric method (BACTEC) and conventional culture media for recovery of 
mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18:384–8.
24. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large 
academic hospital in South Africa. Epidemiol Infect 2005; 133:393–9.
25. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med 
2015; 372:2039–48.
26. Dilauro  S, Crum-Cianflone  NF. Ileitis: when it is not Crohn’s disease. Curr 
Gastroenterol Rep 2010; 12:249–58.
27. Wisnivesky  JP, Kaplan  J, Henschke  C, et  al. Evaluation of clinical parameters 
to predict Mycobacterium tuberculosis in inpatients. Arch Intern Med 2000; 
160:2471–6.
28. Wisnivesky JP, Henschke C, Balentine J, et al. Prospective validation of a predic-
tion model for isolating inpatients with suspected pulmonary tuberculosis. Arch 
Intern Med 2005; 165:453–7.
29. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening 
and diagnosis in people with HIV. N Engl J Med 2010; 362:707–16.
30. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tubercu-
losis and rifampin resistance. N Engl J Med 2010; 363:1005–15.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/6/4/ofz154/5427906 by W
W
Z Bibliothek (O
effentliche Bibliotherk der U
niversitÃ¤t Basel) user on 02 M
ay 2019
